Il y a eu 50 transactions d'initiés récentes enregistrées pour X4 Pharmaceuticals, Inc. (XFOR), dont 34 achats et 12 ventes. Le total des achats d'initiés s'élève à $16.94M et le total des ventes d'initiés à $474.36K.
Les initiés notables ayant une activité récente comprennent Wyzga Michael S, Stewart Murray, De Craecker Francoise. Les transactions d'initiés peuvent fournir des indications sur la façon dont la direction perçoit la valorisation et les perspectives futures de l'action.
Transactions d'Initiés — XFOR
| Date |
Nom |
Rôle |
Type de Transaction |
Actions |
Prix Moyen |
Valeur |
Actions détenues |
| 2026-01-01 |
Wyzga Michael S |
Director |
Attribution de RSU |
110,000 |
$4.00 |
$440K |
- |
| 2026-01-01 |
Stewart Murray |
Director |
Attribution de RSU |
110,000 |
$4.00 |
$440K |
- |
| 2026-01-01 |
De Craecker Francoise |
Director |
Attribution de RSU |
110,000 |
$4.00 |
$440K |
- |
| 2026-01-01 |
Bridger Gary |
Director |
Attribution de RSU |
110,000 |
$4.00 |
$440K |
- |
| 2025-10-29 |
Kirske David |
Chief Financial Officer |
Attribution de RSU |
1,552,769 |
$1.42 |
$2.2M |
1,552,769 |
| 2025-10-29 |
Craig Adam R |
Executive Chairman |
Attribution de RSU |
2,329,154 |
$1.42 |
$3.31M |
2,329,154 |
| 2025-10-29 |
Volpone John |
President |
Attribution de RSU |
2,329,154 |
$1.42 |
$3.31M |
2,329,154 |
| 2025-10-23 |
Craig Adam R |
Executive Chairman |
Achat Informatif |
86,206 |
$2.90 |
$250K |
376,087 |
| 2025-08-14 |
Kirske David |
Chief Financial Officer |
Attribution de RSU |
193,254 |
- |
- |
193,254 |
| 2025-08-14 |
Craig Adam R |
Executive Chairman |
Attribution de RSU |
289,881 |
- |
- |
289,881 |
| 2025-08-14 |
Volpone John |
President |
Attribution de RSU |
289,881 |
- |
- |
289,881 |
| 2025-08-12 |
Kirske David |
Officer |
Inconnu |
- |
- |
- |
- |
| 2025-08-12 |
Kirske David |
Chief Financial Officer |
Attribution de RSU |
1,073,249 |
$1.42 |
$1.52M |
1,073,249 |
| 2025-08-12 |
Craig Adam R |
Executive Chairman |
Inconnu |
- |
- |
- |
- |
| 2025-08-12 |
Craig Adam R |
Executive Chairman |
Attribution de RSU |
1,609,873 |
$1.42 |
$2.29M |
1,609,873 |
| 2025-08-12 |
Volpone John |
Officer |
Inconnu |
- |
- |
- |
- |
| 2025-08-12 |
Volpone John |
President |
Attribution de RSU |
1,609,873 |
$1.42 |
$2.29M |
1,609,873 |
| 2025-06-09 |
Wyzga Michael S |
Director |
Attribution de RSU |
1,500 |
- |
- |
5,555 |
| 2025-06-09 |
Mcgirr David W J |
Director |
Attribution de RSU |
1,500 |
- |
- |
4,722 |
| 2025-06-09 |
Bridger Gary |
Director |
Attribution de RSU |
1,500 |
- |
- |
4,722 |
| 2025-06-09 |
Stewart Murray |
Director |
Attribution de RSU |
1,500 |
- |
- |
7,883 |
| 2025-06-09 |
De Craecker Francoise |
Director |
Attribution de RSU |
1,500 |
- |
- |
4,722 |
| 2025-06-09 |
Woods Keith |
Director |
Attribution de RSU |
1,500 |
- |
- |
6,000 |
| 2025-05-20 |
Thoren Natasha Fay |
Chief Legal Officer |
Inconnu |
8,166 |
$32.70 |
$267.03K |
- |
| 2025-05-20 |
Thoren Natasha Fay |
Chief Legal Officer |
Attribution de RSU |
3,333 |
- |
- |
9,462 |
| 2025-05-16 |
Baldry Mark |
Chief Commercial Officer |
Achat Informatif |
1,032 |
$2.48 |
$2.56K |
25,337 |
| 2025-05-16 |
Baldry Mark |
Chief Commercial Officer |
Attribution de RSU |
1,032 |
$2.48 |
$2.56K |
25,337 |
| 2025-02-12 |
Baldry Mark |
Chief Commercial Officer |
Attribution de RSU |
600,000 |
- |
- |
729,173 |
| 2025-02-12 |
Mostafa Adam S. |
Chief Financial Officer |
Attribution de RSU |
850,000 |
- |
- |
850,000 |
| 2025-02-12 |
Ragan Paula |
President and CEO |
Attribution de RSU |
2,250,000 |
- |
- |
3,337,386 |
| 2025-02-12 |
Arbet-engels Christophe |
Chief Medical Officer |
Attribution de RSU |
850,000 |
- |
- |
864,207 |
| 2025-02-12 |
Dibiase Mary |
Chief Operating Officer |
Attribution de RSU |
650,000 |
- |
- |
1,140,980 |
| 2025-01-24 |
Baldry Mark |
Chief Commercial Officer |
Vente Informative |
29,159 |
$0.45 |
$13.24K |
94,123 |
| 2025-01-24 |
Mostafa Adam S. |
Chief Financial Officer |
Vente Informative |
74,773 |
$0.45 |
$33.95K |
- |
| 2025-01-24 |
Ragan Paula |
President and CEO |
Vente Informative |
76,473 |
$0.45 |
$34.72K |
1,087,386 |
| 2025-01-24 |
Arbet-engels Christophe |
Chief Medical Officer |
Vente Informative |
11,624 |
$0.45 |
$5.28K |
14,207 |
| 2025-01-24 |
Dibiase Mary |
Chief Operating Officer |
Vente Informative |
22,258 |
$0.45 |
$10.09K |
490,980 |
| 2025-01-23 |
Baldry Mark |
Chief Commercial Officer |
Attribution de RSU |
74,773 |
- |
- |
123,282 |
| 2025-01-23 |
Mostafa Adam S. |
Chief Financial Officer |
Attribution de RSU |
74,773 |
- |
- |
74,773 |
| 2025-01-23 |
Ragan Paula |
President and CEO |
Attribution de RSU |
169,940 |
- |
- |
1,163,859 |
| 2025-01-23 |
Arbet-engels Christophe |
Chief Medical Officer |
Attribution de RSU |
25,831 |
- |
- |
25,831 |
| 2025-01-23 |
Dibiase Mary |
Chief Operating Officer |
Attribution de RSU |
61,178 |
- |
- |
513,238 |
| 2024-11-15 |
Baldry Mark |
Chief Commercial Officer |
Achat Informatif |
13,404 |
$0.34 |
$4.6K |
129,173 |
| 2024-11-15 |
Ragan Paula |
President and CEO |
Vente Informative |
31,897 |
$0.39 |
$12.58K |
993,919 |
| 2024-10-15 |
Ragan Paula |
President and CEO |
Vente Informative |
31,897 |
$0.56 |
$17.93K |
1,025,816 |
| 2024-10-07 |
Baldry Mark |
Chief Commercial Officer |
Vente Informative |
11,127 |
$0.58 |
$6.51K |
48,509 |
| 2024-10-07 |
Mostafa Adam S. |
Chief Financial Officer |
Vente Informative |
230,645 |
$0.55 |
$126.9K |
- |
| 2024-10-07 |
Ragan Paula |
President and CEO |
Vente Informative |
239,436 |
$0.55 |
$131.52K |
1,057,713 |
| 2024-10-07 |
Taveras Arthur |
Chief Scientific Officer |
Vente Informative |
76,920 |
$0.56 |
$43.31K |
388,026 |
| 2024-10-07 |
Dibiase Mary |
Chief Operating Officer |
Vente Informative |
67,695 |
$0.57 |
$38.33K |
452,060 |
■ Informatif — transaction sur marché ouvert (la plus significative)
■ Non informatif (achat) — récompense, exercice d'option, conversion
■ Non informatif (vente) — retenue fiscale, vente à l'acquisition
■ Neutre — don, fiducie, expiration
Les autres consultent aussi
